Dapagliflozin for HFrEF fast-tracked onto PBS
GPs now have the opportunity to take a leading role in HF management, says Dr Anita Sharma
Dapagliflozin is now a PBS-listed treatment for symptomatic heart failure with a reduced ejection fraction, but only in combination with standard therapy.
The new indication and clinical criteria for the SGLT2 inhibitor was added to the PBS on 1 January, less than three months after getting the green light from the PBAC.
Federal Minister for Health Greg Hunt said some 75,000 Australians a year would benefit, estimating that for every 100 patients treated with dapagliflozin (Forxiga) in addition to standard
